Prolonged-Release Melatonin After 55 | Slumbr

South Africa has exactly one melatonin product registered as a full medicine, and it is aimed at a specific person: an adult aged 55 or over with months of poor-quality sleep. It is a 2 mg prolonged-release tablet, prescription-only, taken one to two hours before bed for a course of up to thirteen weeks. It is not a stronger version of the low-dose melatonin travellers buy for jet lag. It is a different tool built on a different idea: replacing an evening hormone signal that fades with age.

Key takeaways

The registered product's licensed indication is precise: short-term treatment, up to 13 weeks, of primary insomnia characterised by poor quality of sleep, in patients aged 55 or over.
The logic is replacement. Natural melatonin output declines with age, and this tablet releases 2 mg slowly across the night to mimic the fading profile.
Approved directions: 2 mg once daily, one to two hours before bedtime, after food, swallowed whole. Crushing or chewing destroys the slow-release mechanism.
Its trial safety record is genuinely mild, with the most common adverse reactions sitting in the uncommon band, and it carries no established dependence risk, unlike conventional sleeping tablets.
Efficacy in under-55s has not been demonstrated, per its own approved information. This is not a general-purpose sleeping aid.
Even in the right patient, guidelines still put CBT-I first for chronic insomnia. The tablet is an option alongside, not instead.

Why age changes the melatonin question

Through adult life, the pineal gland's evening melatonin signal weakens: output declines and the night-time peak flattens. Around and after the mid-fifties, that flattening becomes one plausible contributor to a familiar cluster of complaints. Sleep gets shallower, more broken, and less refreshing, even when its total hours look adequate on paper.

This is the one scenario where "take melatonin for insomnia" has real regulatory and clinical backing, because the intervention matches a deficit. A 30-year-old with racing-mind insomnia has a normal melatonin signal, so adding more treats nothing. A 68-year-old with poor-quality sleep may genuinely be missing part of the signal, and replacing it is a rational move. That is why the licensed indication has an age floor, and why the product's own information notes that efficacy in patients younger than 55 has not been demonstrated.

Why "prolonged-release" is the point

Ordinary melatonin is cleared quickly. A low immediate-release dose produces a brief evening pulse, which is exactly right for nudging a body clock and exactly wrong for supporting an entire night in someone whose own production has faded.

The registered product is engineered around that problem: 2 mg released gradually, approximating the shape of a natural night-time profile rather than a spike. Two practical consequences follow directly from the design.

Swallow it whole. Crushed or chewed, it becomes an immediate-release dose and the entire rationale collapses. If swallowing tablets is difficult, tell the prescriber rather than improvising.

Take it at the approved time, one to two hours before bed, after food. This is a scheduled replacement signal, not an as-needed rescue tablet. It is also worth knowing it may cause drowsiness, so treat the post-dose window as the end of your day, not a time to drive.

What a fair trial looks like

This is a course, not a lifestyle: the licence runs to thirteen weeks. Improvement, when it comes, tends to build over the first weeks, showing up as better sleep quality and fresher mornings rather than a dramatic knockout effect on night one. Anyone expecting a sedative punch will be underwhelmed, which is the correct experience for a physiological dose of a hormone.

At the end of a course, prescriber and patient review honestly. Better, and by enough? Worth a repeat course later, or has CBT-I work in parallel changed the picture? No benefit at all is an answer too, and it steers attention back to other causes of broken sleep in this age group, several of which matter more.

The safety profile, from its own documentation

Because this is a registered medicine, its approved professional information includes a full adverse-reaction table from clinical trials, and it is one of the milder ones in sleep medicine. The most commonly reported reactions (headache, cold-like symptoms, back pain, joint pain) all sat in the uncommon frequency band, meaning fewer than 1 in 100 participants. There is no tolerance spiral, no withdrawal syndrome, and no rebound insomnia on stopping. That is the trap that makes conventional sleeping tablets unsuitable for exactly this age group, in which sedatives also raise fall and confusion risks.

Mild does not mean unconditional. From the approved information:

Not recommended: under-18s; hepatic impairment, because melatonin clearance is already reduced; autoimmune disease, because no clinical data exist.
Contraindicated: pregnancy and breastfeeding, because safety has not been established.
Caution: kidney impairment; diabetes, since the tablet contains lactose and melatonin interacts with glucose handling; anyone with galactose intolerance.
Interactions: fluvoxamine is the standout, raising melatonin levels dramatically, and the combination should be avoided. Oestrogens, cimetidine and quinolones raise levels; carbamazepine, rifampicin and smoking lower them; alcohol reduces its effect on sleep and should not be taken with it; combined with benzodiazepines or z-drugs it can add sedation.
Driving: it may cause somnolence or dizziness, so no driving or machinery after the dose.

A prescriber screens for all of this in minutes. This is much of what the prescription requirement is for.

What it will not fix

The licensed indication says "primary insomnia" deliberately. Poor sleep after 55 has a differential that a hormone cannot treat: sleep apnoea (snoring, witnessed pauses, morning headaches), restless legs, nocturia, pain, and depression, whose early-morning-waking signature deserves particular respect in this age group. Add medication effects, from evening diuretics to beta-blockers, which ironically suppress natural melatonin.

This is why the pathway runs through a doctor rather than a shelf, and why at Slumbr the consultation starts with pattern and screening rather than a script pad. Prolonged-release melatonin is a good tool for the patient it was licensed for, after the look-alikes are ruled out. And for chronic insomnia at any age, CBT-I remains the first-line treatment in every major guideline. In the right older patient, the two work well together.

Frequently asked questions

What is the difference between prolonged-release and normal melatonin? Release shape. Immediate-release gives a brief evening pulse, right for shifting a body clock. Prolonged-release spreads 2 mg across the night to mimic the natural profile that fades with age, right for sleep quality in older adults. They are not interchangeable, and you cannot turn one into the other by splitting tablets.

Do I need a prescription for slow-release melatonin in South Africa? Yes. It is a Schedule 4 medicine. The only melatonin a pharmacist can sell without a script is for jet lag, at up to 6 mg daily, under the Schedule 2 carve-out.

How long can I take it? The licence covers a course of up to thirteen weeks. Whether to repeat is a review decision with your prescriber, not an automatic refill.

I'm 45 and sleep badly. Can I use it? Its approved information states efficacy under 55 has not been demonstrated. At 45, poor sleep is far more likely to be insomnia-by-conditioning, which responds to CBT-I rather than hormone replacement.

Is it addictive? No. No tolerance, no withdrawal, no rebound insomnia. That safety margin in an age group vulnerable to sedative harms is precisely why it exists as an option.

Does it work the first night? Usually not dramatically, and that is expected. It is a physiological replacement, not a sedative, so benefits accrue over weeks of a course.

Prolonged-Release Melatonin: The Prescription Option for Insomnia After 55